株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

季節性インフルエンザワクチン - 日本における医薬品の予測と市場分析

Seasonal Influenza Vaccines - Japan Drug Forecast and Market Analysis to 2025

発行 GlobalData 商品コード 258670
出版日 ページ情報 英文 246 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.44円で換算しております。
Back to Top
季節性インフルエンザワクチン - 日本における医薬品の予測と市場分析 Seasonal Influenza Vaccines - Japan Drug Forecast and Market Analysis to 2025
出版日: 2016年11月01日 ページ情報: 英文 246 Pages
概要

当レポートでは、日本の季節性インフルエンザワクチン市場について調査し、市場の概要、競合情勢、主要薬剤の詳細情報とSWOT分析、主要薬剤の売上予測、主要イベントの影響分析、市場影響因子の分析などをまとめています。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
  • 症状
  • 予後

第4章 疾病管理

  • インフルエンザ予防接種政策
  • 日本

第5章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド - 不活化ワクチン
  • 製品プロファイル:主要ブランド - 不活化ワクチン (アジュバント)
  • 製品プロファイル:主要ブランド - 弱毒化ワクチン
  • 製品プロファイル:主要ブランド - 細胞培養ワクチン
  • その他

第6章 機会・アンメットニーズ

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望薬剤
  • 早期開発中の有望薬剤

第8章 市場展望

  • 日本
    • 予測
    • 主なイベント
    • 促進因子・阻害因子

第9章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC373CFR

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection's rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

The projected drivers for growth of the Japanese influenza vaccine market include the entrance of large multinational firms into the marketplace, a government commitment to educating the populace about the importance of preventative medicine (including vaccination), and growth of the elderly population.

Scope

  • Overview of Seasonal Influenza Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2015-2025.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan Seasonal Influenza Vaccines market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Seasonal Influenza Vaccines.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2015-2025 in Japan.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 10

2 Introduction 11

  • 2.1 Catalyst 11
  • 2.2 Related Reports 12
  • 2.3 Upcoming Related Reports 12

3 Disease Overview 13

  • 3.1 Etiology and Pathophysiology 13
    • 3.1.1 Etiology 13
    • 3.1.2 Pathophysiology 18
    • 3.1.3 Symptoms and Prognosis 19

4 Disease Management 21

  • 4.1 Seasonal Influenza Immunization Policy 21
    • 4.1.1 Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines 22
  • 4.2 Japan 24
    • 4.2.1 Influenza Immunization Recommendations and Policies 25
    • 4.2.2 Clinical Practice 27

5 Competitive Assessment 30

  • 5.1 Overview 30
  • 5.2 Product Profiles - Major Brands, Inactivated Vaccines 32
    • 5.2.1 Fluzone Quadrivalent 32
    • 5.2.2 Fluzone High-Dose 38
    • 5.2.3 Fluzone Intradermal 45
    • 5.2.4 Vaxigrip 53
    • 5.2.5 Fluarix Tetra 59
    • 5.2.6 Fluvirin 66
    • 5.2.7 Afluria 71
    • 5.2.8 Agrippal 77
  • 5.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted) 81
    • 5.3.1 Fluad 81
  • 5.4 Product Profiles - Major Brands, Live-Attenuated Vaccines 88
    • 5.4.1 FluMist Quadrivalent 88
  • 5.5 Product Profiles - Major Brands, Cell Cultured Vaccines 96
    • 5.5.1 Flublok 96
    • 5.5.2 Flucelvax 103
  • 5.6 Other Seasonal Influenza Vaccines 110
    • 5.6.1 Influvac 110
    • 5.6.2 Minor Brands 112

6 Unmet Needs and Opportunity Analysis 113

  • 6.1 Overview 113
  • 6.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines 117
    • 6.2.1 Unmet Need 117
    • 6.2.2 Gap Analysis 118
    • 6.2.3 Opportunity 121
  • 6.3 Immunization Policies Targeting Children and Adolescents 122
    • 6.3.1 Unmet Need 122
    • 6.3.2 Gap Analysis 123
    • 6.3.3 Opportunity 123
  • 6.4 Enhanced Vaccine Efficacy in High-Risk Groups 125
    • 6.4.1 Unmet Need 125
    • 6.4.2 Gap Analysis 126
    • 6.4.3 Opportunity 128
  • 6.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies 129
    • 6.5.1 Unmet Need 129
    • 6.5.2 Gap Analysis 130
    • 6.5.3 Opportunity 131
  • 6.6 Improving the Cost-Effectiveness of Influenza Vaccines 132
    • 6.6.1 Unmet Need 132
    • 6.6.2 Gap Analysis 133
    • 6.6.3 Opportunity 134
  • 6.7 Vaccines with Broader Influenza Strain Coverage 135
    • 6.7.1 Unmet Need 135
    • 6.7.2 Gap Analysis 136
    • 6.7.3 Opportunity 137
  • 6.8 Improved Vaccine Safety Profile 138
    • 6.8.1 Unmet Need 138
    • 6.8.2 Gap Analysis 139
    • 6.8.3 Opportunity 140

7 Pipeline Assessment 141

  • 7.1 Overview 141
  • 7.2 Promising Vaccines in Clinical Development 142
    • 7.2.1 Seasonal Influenza VLP Vaccine 147
    • 7.2.2 VN-100 156
    • 7.2.3 Quadrivalent Seasonal Influenza VLP Vaccine 164
  • 7.3 Promising Vaccines in Early-Stage Development 172
    • 7.3.1 FLU-v 173
    • 7.3.2 M-001 174
    • 7.3.3 TAK-850 175
    • 7.3.4 VAX-2012Q 175
  • 7.4 Other Vaccines in Development Outside the 7MM 176

8 Market Outlook 177

  • 8.1 Japan 177
    • 8.1.1 Forecast 177
    • 8.1.2 Key Events 181
    • 8.1.3 Drivers and Barriers 182

9 Appendix 183

  • 9.1 Bibliography 183
  • 9.2 Abbreviations 221
  • 9.3 Methodology 225
  • 9.4 Forecasting Methodology 225
    • 9.4.1 Vaccine Coverage 225
    • 9.4.2 Vaccines Included 226
    • 9.4.3 Key Launch Dates 226
    • 9.4.4 Influenza Vaccine Tender System Assumptions 227
    • 9.4.5 General Pricing Assumptions 228
    • 9.4.6 Individual Vaccine Assumptions 229
    • 9.4.7 Pricing of Pipeline Agents 237
  • 9.5 Primary Research - KOLs Interviewed for this Report 238
  • 9.6 Primary Research - Prescriber Survey 241
  • 9.7 About the Authors 242
    • 9.7.1 Analyst 242
    • 9.7.2 Therapy Area Director 242
    • 9.7.3 Epidemiologists 243
    • 9.7.4 Director of Epidemiology 244
    • 9.7.5 Global Director of Therapy Analysis and Epidemiology 244
  • 9.8 About GlobalData 245
  • 9.9 Disclaimer 245

List of Tables

  • Table 1: Notable Influenza Pandemics 18
  • Table 2: Influenza Symptoms 20
  • Table 3: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016 22
  • Table 4: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016 24
  • Table 5: Country Profile -Japan 25
  • Table 6: Leading Seasonal Influenza Vaccines, 2016 31
  • Table 7: Product Profile - Fluzone Quadrivalent 33
  • Table 8: Immunogenicity Profile of Fluzone Quadrivalent 34
  • Table 9: Local and Systemic AEs of Fluzone Quadrivalent 35
  • Table 10: Fluzone Quadrivalent SWOT Analysis, 2016 36
  • Table 11: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025 38
  • Table 12: Product Profile - Fluzone High-Dose 39
  • Table 13: Immunogenicity of Fluzone High-Dose Compared with Fluzone 41
  • Table 14: Local and Systemic AEs of Fluzone High-Dose 42
  • Table 15: Fluzone High-Dose SWOT Analysis, 2016 43
  • Table 16: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025 45
  • Table 17: Product Profile - Fluzone Intradermal 47
  • Table 18: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent 49
  • Table 19: Local andsystemic AEs of Fluzone Intradermal Quadrivalent 50
  • Table 20: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016 51
  • Table 21: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025 53
  • Table 22: Product Profile - Vaxigrip 55
  • Table 23: Cumulative Incidence of Influenza Infection in Children 56
  • Table 24: Local and Systemic AEs of Vaxigrip 57
  • Table 25: Vaxigrip SWOT Analysis, 2016 57
  • Table 26: Global Sales Forecast ($m) for Vaxigrip, 2015-2025 59
  • Table 27: Product Profile - Fluarix Tetra 61
  • Table 28: Immunogenicity Profile of Fluarix Tetra 62
  • Table 29: Local and Systemic AEs of Fluarix Tetra 63
  • Table 30: Fluarix Tetra SWOT Analysis, 2016 64
  • Table 31: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025 66
  • Table 32: Product Profile - Fluvirin 67
  • Table 33: Immunogenicity of Fluvirin in Adults 68
  • Table 34: Local and Systemic AEs of Fluvirin 69
  • Table 35: Fluvirin SWOT Analysis, 2016 70
  • Table 36: Global Sales Forecast ($m) for Fluvirin, 2015-2025 71
  • Table 37: Product Profile - Afluria 72
  • Table 38: Immunogenicity of Afluria in Adults 73
  • Table 39: Local and Systemic AEs of Afluria 74
  • Table 40: Afluria SWOT Analysis, 2016 75
  • Table 41: Global Sales Forecast ($m) for Afluria, 2015-2025 76
  • Table 42: Product Profile - Agrippal 78
  • Table 43: Immunogenicity of Agrippal 79
  • Table 44: Local and Systemic AEs of Agrippal 79
  • Table 45: Agrippal SWOT Analysis, 2016 80
  • Table 46: Global Sales Forecast ($m) for Agrippal, 2015-2025 81
  • Table 47: Product Profile - Fluad 83
  • Table 48: Immunogenicity Comparison of Fluad Versus Agriflu 84
  • Table 49: Local and Systemic AEs of Fluad 85
  • Table 50: Fluad SWOT Analysis, 2016 86
  • Table 51: Global Sales Forecast ($m) for Fluad, 2015-2025 88
  • Table 52: Product Profile - FluMist Quadrivalent 90
  • Table 53: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent 92
  • Table 54: AEs of FluMist Quadrivalent 93
  • Table 55: FluMist Quadrivalent SWOT Analysis, 2016 93
  • Table 56: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025 95
  • Table 57: Product Profile - Flublok 97
  • Table 58: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose 99
  • Table 59: Local and Systemic AEs of Flublok 100
  • Table 60: Flublok SWOT Analysis, 2016 101
  • Table 61: Global Sales Forecast ($m) for Flublok, 2015-2025 103
  • Table 62: Product Profile - Flucelvax 105
  • Table 63: Immunogenicity of Flucelvax 106
  • Table 64: Local and Systemic AEs of Flucelvax 107
  • Table 65:Flucelvax SWOT Analysis, 2016 108
  • Table 66: Global Sales Forecast ($m) for Flucelvax, 2015-2025 110
  • Table 67: Summary of Other Marketed Seasonal Influenza Vaccines, 2016 112
  • Table 68: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016 116
  • Table 69: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016 143
  • Table 70: Quadrivalent Versions of Marketed Vaccines 146
  • Table 71: Product Profile - Seasonal Influenza VLP Vaccine 149
  • Table 72: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 154
  • Table 73: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025 156
  • Table 74: Product Profile - VN-100 158
  • Table 75: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine 159
  • Table 76: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine 160
  • Table 77: VN-100 SWOT Analysis, 2016 163
  • Table 78: Global Sales Forecast ($m) for VN-100, 2015-2025 164
  • Table 79: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine 166
  • Table 80: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 170
  • Table 81: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025 172
  • Table 82: Promising Vaccines in Early-Stage Development, 2016 173
  • Table 83: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016 176
  • Table 84: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015-2025 179
  • Table 85: Key Events Impacting Sales for Seasonal Influenza in Japan 2015?2025 181
  • Table 86: Japan Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025 182
  • Table 87: Key Launch Dates 227
  • Table 88: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 241

List of Figures

  • Figure 1: Influenza Virus Structure 15
  • Figure 2: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016 143
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025 144
  • Figure 4: Sales of Seasonal Influenza Vaccines by Class in Japan, 2015 and 2025 180
Back to Top